---
url: https://www.servicesaustralia.gov.au/ankylosing-spondylitis-toxicity-and-severity-descriptors
title: Ankylosing spondylitis toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:43:47.815Z
source: servicesaustralia.gov.au
---
# Ankylosing spondylitis toxicity and severity descriptors

Toxicity and severity descriptors for Nonsteroidal Anti-inflammatory Drug (NSAID) therapy required to be trialled before accessing PBS-subsidised biological medicines to treat ankylosing spondylitis.

Use the following toxicity and severity descriptors with the authority application when demonstrating a patient’s intolerance to NSAID treatment.

Adverse event

Brief description of minimum grade

National Institutes of Health common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin <80 g per L

3 (or higher)

Haemolysis

Evidence of red cell destruction and >20 g per L drop in haemoglobin, no transfusion required

2 (or higher)

Leukopaenia

Total white cell count < 3 × 109 per L

2 (or higher)

Neutropaenia

Neutrophils <1.0 × 109 per L

3 (or higher)

Thrombocytopaenia

Platelets <50 × 109 per L

3 (or higher)

**Cardiovascular**

Arrhythmia

Symptomatic and requiring therapy

3 (or higher)

Cardiac left ventricle function

Congestive cardiac failure responsive to treatment

3 (or higher)

Hypertension

Recurrent or persistent rise of >20 mmHg diastolic blood pressure or rise to >150/90 on 2 occasions if blood pressure previously normal

2 (or higher)

Myocardial ischaemia or infarction

Unstable angina or myocardial infarction

3 (or higher)

Oedema

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Coagulation**

Prothrombin time

Prothrombin time >2 × upper limit of normal

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Photosensitivity

Painful erythema or bullae

2 (or higher)

Pruritis

Intense or widespread and poorly controlled despite treatment

3 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering <50% of body surface, or localised desquamation or other lesions covering <50% of body surface

2 (or higher)

Urticaria

Requiring topical, oral or IV medication for <24 hours

2 (or higher)

**Gastrointestinal**

Abdominal pain

Moderate pain, interfering with function

2 (or higher)

Anorexia

Oral intake significantly decreased

2 (or higher)

Constipation

Requiring use of laxatives and enemas

3 (or higher)

Diarrhoea

Increase of 4-6 stools per day over pretreatment

2 (or higher)

Dyspepsia

Moderate or severe, unresponsive to standard therapy, recurs on rechallenge

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Peptic ulcer

Requiring medical management

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Haemorrhage**

Melena or gastrointestinal bleeding

Requiring transfusion

3 (or higher)

Purpura

Generalised purpura

3 (or higher)

**Hepatic**

Bilirubin

\>1.5 × upper limit of normal

2 (or higher)

Transaminases

Alanine aminotransferase or  
aspartate aminotransferase >2.5 × upper limit of normal or  
alanine aminotransferase or  
aspartate aminotransferase >1.5 × upper limit of normal on 3 occasions over a 3-month period

2 (or higher)

**Neurology or senses**

Central nervous system cerebrovascular ischaemia

Transient ischaemic attack or cerebrovascular accident

3 (or higher)

Decreased level of consciousness

Somnolence or sedation, interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain. Pain or analgesics severely interfering with activities of daily living

3 (or higher)

Inner ear or hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Insomnia

Frequent difficulty sleeping, interfering with activities of daily living

3 (or higher)

Mood alteration

Moderate mood alteration, interfering with function but not interfering with activities of daily living

2 (or higher)

Neuropathy - sensory

Objective sensory loss or paraesthesia, interfering with function but not interfering with activities of daily living

2 (or higher)

Vertigo

Interfering with activities of daily living

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Pulmonary**

Asthma

Moderate

2 (or higher)

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment

3 (or higher)

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

**Renal**

Haematuria

Macroscopic haematuria

2 (or higher)

Hyperkalaemia

\>6.0 mmol per L

3 (or higher)

Proteinuria

\>1.0 g per 24 hours, elevated urine protein:creatinine ratios >100 mg per mmol, dipstick protein ++ or greater, confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine >1.5 upper limit of normal or creatinine clearance <30 mL per min

2 (or higher)

**Other**

Allergic reaction or hypersensitivity

Urticaria, drug fever >38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)
